20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
20/20 BioLabs (Nasdaq: AIDX) entered an exclusive U.S. license and access agreement with ROKIT Healthcare to integrate ROKIT’s proprietary chronic kidney disease (CKD) prediction algorithm into 20/20’s Longevity Platform, adding CKD risk assessment to its OneTest for Longevity offering.
Under the deal, ROKIT will reimburse one-third of mutually agreed sales and marketing expenses and receive a running royalty on net sales; the parties also anticipate negotiating separate exclusive commercialization rights for Korea and possibly other East Asian markets. The integration targets earlier CKD detection and enhanced biomarker-driven decision support for patients and providers.
Positive
- Exclusive U.S. technology license to integrate ROKIT CKD algorithm
- ROKIT to reimburse one-third of agreed sales and marketing expenses
- Adds CKD risk assessment to OneTest for Longevity
- Potential exclusive commercialization rights in Korea and East Asia
Negative
- Running royalty to ROKIT on net sales will reduce product margins
- Korean and East Asian commercialization rights are only anticipated, not finalized
Details
News Market Reaction – AIDX
On Mar 24, the day this news came out, AIDX closed 17.59% below the previous close.
Data tracked by StockTitan Argus for the Mar 24 session.
Key Figures
- Sales & marketing share
- One-third of mutually agreed expenses
- ROKIT reimbursement for sales and marketing under U.S. license agreement
- CKD prevalence US
- More than 35 million Americans
- Chronic kidney disease burden referenced for risk assessment market
- Current price
- $2.0185
- Pre-news trading level on publication date
- 52-week high
- $50
- Reference high versus current longevity platform expansion
- 52-week low
- $1.6991
- Recent downside reference before CKD licensing announcement
- Market cap
- $20,923,138
- Equity value prior to CKD prediction licensing news
Historical Context
-
Highlighted validation data for patented protein biomarker multi-cancer detection.
-
Launched AI-enabled OneTest for Longevity chronic disease risk platform.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
chronic kidney disease medical
ckd medical
biomarker medical
inflammatory biomarkers medical
3-d bio-printed tissue patches medical
algorithm technical
regenerative therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Inflammatory Biomarker Tracking Predicted to Enhance
Response to 3-D Bio-Printed Therapies
Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment
GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”), 20/20 BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare Inc. (“ROKIT”), a global innovator in chronic disease prediction and regenerative health technologies. Under the agreement, 20/20 will integrate ROKIT’s proprietary chronic kidney disease (CKD) prediction algorithm into the 20/20 Longevity Platform, expanding its suite of biomarker-based disease-risk assessment tools.
Under the agreement, ROKIT agreed to reimburse 20/20 for one-third of mutually agreed sales and marketing expenses in exchange for a running royalty to ROKIT on net sales of the combined product. The companies also anticipate negotiating a separate agreement under which ROKIT may receive exclusive rights to commercialize 20/20’s longevity platform in Korea and potentially other East Asian markets.
Clinical evidence suggests that patients with lower systemic inflammation, as measured by biomarkers such as CRP, the centerpiece of OneTest for Longevity, tend to experience more favorable biological responses to regenerative therapies such as ROKIT’s 3‑D bio-printed tissue patches for burns, chronic kidney disease and heart failure.
“20/20 Biolabs has created an elegant solution to help patients lower their levels inflammatory biomarkers through evidence based dietary and lifestyle changes,” noted Wonkyung Choi, Vice President of R&D, Rokit Healthcare. “We expect that patients being treated for burns or chronic kidney disease using our 3-D bio-printed patches will likely have better outcomes if they can lower their inflammation and maintain those low levels through biomarker tracking and better food choices over time using OneTest for Longevity” continued Choi.
The addition of CKD prediction capabilities enhances 20/20’s competitive position in the rapidly expanding longevity-analytics sector. Chronic kidney disease affects more than 35 million Americans, and early detection remains one of the most effective strategies for slowing progression. By integrating ROKIT’s predictive model, 20/20 aims to deliver earlier insights, more personalized risk trajectories, and improved decision-support tools for individuals and their healthcare providers.
“This agreement is a strong validation of our platform strategy,” said Jonathan Cohen, President & CEO of 20/20 Biolabs. “We believe that combining advanced biomarker tracking with evidence based nutritional support will help improve therapeutic outcomes across multiple chronic disease areas.”
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for Longevity, which measures inflammatory biomarkers, launched in February 2026. OneTest’s affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD.
20/20 BioLabs’ pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab. The Company’s legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. For more information visit 2020biolabs.com.
About ROKIT Healthcare
ROKIT Healthcare (KOSDAQ) is a global leader in regenerative medicine, predictive health analytics, and 3-D bioprinting technologies. The company develops advanced algorithms and regenerative solutions aimed at improving outcomes in chronic disease and tissue repair.
Forward-Looking Statements
Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions. Actual results may differ materially from those expressed or implied by such forward-looking statements. A number of factors could cause actual results to differ materially from those contained in these forward-looking statements, including, but not limited to, the risks described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), available on the SEC’s website at www.sec.gov, including the Company’s Registration Statement on Form S-1, as amended (File No. 333-292125), as well as in our other reports filed or furnished from time to time with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law. Although the Company believes the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee future results, and investors are cautioned that actual outcomes may differ materially from those anticipated.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.